microRNAs in lipoprotein metabolism and cardiometabolic disorders

Atherosclerosis

Volumn 246, Issue , 2016, Pages 352-360

  Rotllan, Noemi ^a   Price, Nathan ^a   Pati, Paramita ^a   Goedeke, Leigh ^a   Fernández Hernando, Carlos ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Lipid metabolism; MicroRNAs

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 122; MICRORNA 30C; MICRORNA 33A; MICRORNA 33B; UNCLASSIFIED DRUG; ABCA1 PROTEIN, HUMAN; BIOLOGICAL MARKER; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DYSLIPIDEMIA; FATTY LIVER; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; ATHEROSCLEROSIS; BLOOD; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; LIPID METABOLISM; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; BIOMARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; LIPID METABOLISM; MICRORNAS; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL;

EID: 84956696730     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.025     Document Type: Review

References (92)

1. American Heart Association 2015 Heart Disease and Stroke Statistics Update 2015.
2. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell 2001, 104:503-516.
3. Brown M.S., Goldstein J.L. Familial hypercholesterolemia: a genetic defect in the low-density lipoprotein receptor. N. Engl. J. Med. 1976, 294:1386-1390.
4. Cuchel M., Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 2006, 113:2548-2555.
5. Fruchart J.C., De Geteire C., Delfly B., et al. Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis 1994, 110(Suppl. l):S35-S39.
6. Tang C., Oram J.F. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim. Biophys. Acta 2009, 1791:563-572.
7. Brown M.S., Goldstein J.L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 1980, 21:505-517.
8. Fernandez-Hernando C., Ramirez C.M., Goedeke L., et al. MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33:178-185.
9. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
10. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
11. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9:102-114.
12. Krek A., Grun D., Poy M.N., et al. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37:495-500.
13. Grimson A., Farh K.K., Johnston W.K., et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
14. Valadi H., Ekstrom K., Bossios A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell. Biol. 2007, 9:654-659.
15. Zernecke A., Bidzhekov K., Noels H., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal 2009, 2:ra81.
16. Vickers K.C., Palmisano B.T., Shoucri B.M., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell. Biol. 2011, 13:423-433.
17. Arroyo J.D., Chevillet J.R., Kroh E.M., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5003-5008.
18. Pan S., Yang X., Jia Y., et al. Microvesicle-shuttled miR-130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-gamma expression. J. Cell. Physiol. 2014, 229:631-639.
19. Wang Y.C., Li Y., Wang X.Y., et al. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia 2013, 56:2275-2285.
20. Price N.L., Ramirez C.M., Fernandez-Hernando C. Relevance of microRNA in metabolic diseases. Crit. Rev. Clin. Lab. Sci. 2014, 51:305-320.
21. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999, 22:336-345.
22. Bodzioch M., Orso E., Klucken J., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 1999, 22:347-351.
23. Lawn R.M., Wade D.P., Garvin M.R., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. investig. 1999, 104:R25-R31.
24. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 1999, 22:352-355.
25. de Aguiar Vallim T.Q., Tarling E.J., Edwards P.A. Pleiotropic roles of bile acids in metabolism. Cell. metab. 2013, 17:657-669.
26. Esteller A. Physiology of bile secretion. World J. gastroenterol. WJG 2008, 14:5641-5649.
27. Paulusma C.C., Folmer D.E., Ho-Mok K.S., et al. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology 2008, 47:268-278.
28. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell. Biol. 2012, 13:239-250.
29. Rayner K.J., Suarez Y., Davalos A., et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010, 328:1570-1573.
30. Najafi-Shoushtari S.H., Kristo F., Li Y., et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010, 328:1566-1569.
31. Davalos A., Goedeke L., Smibert P., et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9232-9237.
32. Horie T., Ono K., Horiguchi M., et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17321-17326.
33. Ramirez C.M., Goedeke L., Rotllan N., et al. MicroRNA 33 regulates glucose metabolism. Mol. Cell. Biol. 2013, 33:2891-2902.
34. Marquart T.J., Allen R.M., Ory D.S., et al. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:12228-12232.
35. Karunakaran D., Thrush A.B., Nguyen M.A., et al. Macrophage mitochondrial energy status regulates cholesterol efflux and is enhanced by anti-miR33 in atherosclerosis. Circ. Res. 2015, 117:266-278.
36. Allen R.M., Marquart T.J., Albert C.J., et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol. Med. 2012, 4:882-895.
37. Li T., Francl J.M., Boehme S., et al. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7alpha-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice. Hepatology 2013, 58:1111-1121.
38. Rotllan N., Ramirez C.M., Aryal B., et al. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice-brief report. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1973-1977.
39. Rayner K.J., Esau C.C., Hussain F.N., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011, 478:404-407.
40. Rayner K.J., Sheedy F.J., Esau C.C., et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Investig. 2011, 121:2921-2931.
41. Horie T., Baba O., Kuwabara Y., et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J. Am. Heart Assoc. 2012, 1:e003376.
42. Rottiers V., Obad S., Petri A., et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci. Transl. Med. 2013, 5(212):ra162.
43. Horie T., Nishino T., Baba O., et al. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Sci. Rep. 2014, 4:5312.
44. Rayner K.J., Sheedy F.J., Esau C.C., et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Investig. 2011, 121:2921-2931.
45. Horie T., Baba O., Kuwabara Y., et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J. Am. Heart Assoc. 2012, 1.
46. Marquart T.J., Wu J., Lusis A.J., et al. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2013, 33:455-458.
47. Ouimet M., Ediriweera H.N., Gundra U.M., et al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J. Clin. Invest. 2015, 2015.
48. Goedeke L., Salerno A., Ramírez C.M., et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol. Med. 2014, 6:1133-1141.
49. Allen R.M., Marquart T.J., Jesse J.J., et al. Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33. Circ. Res. 2014, 115:10-22.
50. Horie T., Nishino T., Baba O., et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat. Commun. 2013, 4:2883.
51. Karunakaran D., Richards L., Geoffrion M., et al. Therapeutic inhibition of miR-33 promotes fatty acid oxidation but does not Ameliorate metabolic dysfunction in diet-induced obesity. Arterioscler. Thromb. Vasc. Biol. 2015, 12:2536-2543.
52. Ramirez C.M., Davalos A., Goedeke L., et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2707-2714.
53. de Aguiar Vallim T., Tarling E., Kim T., et al. MicroRNA-144 regulates hepatic ABCA1 and plasma HDL following activation of the nuclear receptor FXR. Circ. Res. 2013, 112:1602-1612.
54. Ramirez C.M., Rotllan N., Vlassov A.V., et al. Control of cholesterol metabolism and plasma HDL levels by miRNA-144. Circ. Res. 2013, 112:1592-1601.
55. Shirasaki T., Honda M., Shimakami T., et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J. Virol. 2013, 87:5270-5286.
56. Zhang M., Wu J.F., Chen W.J., et al. MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages. Atherosclerosis 2014, 234:54-64.
57. Goedeke L., Rotllan N., Ramirez C.M., et al. miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice. Atherosclerosis 2015, 243:499-509.
58. Sun D., Zhang J., Xie J., et al. MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett. 2012, 586:1472-1479.
59. Goedeke L., Rotllan N., Canfran-Duque A., et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat. Med. 2015, 21:1280-1289.
60. Wagschal A., Najafi-Shoushtari S.H., Wang L., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat. Med. 2015, 21:1290-1297.
61. Meiler S., Baumer Y., Toulmin E., et al. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015, 35:323-331.
62. Wang L., Jia X.J., Jiang H.J., et al. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol. Cell. Biol. 2013, 33:1956-1964.
63. Wang D., Xia M., Yan X., et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ. Res. 2012, 111:967-981.
64. Tabet F., Vickers K.C., Cuesta Torres L.F., et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat. Commun. 2014, 5:3292.
65. Vickers K.C., Landstreet S.R., Levin M.G., et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:14518-14523.
66. Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89:331-340.
67. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest 2002, 109:1125-1131.
68. Horton J.D., Shimomura I. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol. 1999, 10:143-150.
69. Osborne T.F. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J. Biol. Chem. 2000, 275:32379-32382.
70. Lagos-Quintana M., Rauhut R., Yalcin A., et al. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002, 12:735-739.
71. Chang J., Nicolas E., Marks D., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004, 1:106-113.
72. Esau C., Davis S., Murray S.F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
73. Elmen J., Lindow M., Silahtaroglu A., et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008, 36:1153-1162.
74. Tsai W.C., Hsu S.D., Hsu C.S., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. investig. 2012, 122:2884-2897.
75. Hsu S.H., Wang B., Kota J., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. investig. 2012, 122:2871-2883.
76. Esau C., Davis S., Murray S.F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
77. Hsu S.H., Wang B., Kota J., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 2012, 122:2871-2883.
78. Tsai W.C., Hsu S.D., Hsu C.S., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 2012, 122:2884-2897.
79. Soh J., Iqbal J., Queiroz J., et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat. Med. 2013, 19:892-900.
80. Alvarez M.L., Khosroheidari M., Eddy E., et al. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis 2015, 242:595-604.
81. Jeon T.I., Esquejo R.M., Roqueta-Rivera M., et al. An SREBP-responsive microRNA operon contributes to a regulatory loop for intracellular lipid homeostasis. Cell Metab. 2013, 18:51-61.
82. Yang M., Liu W., Pellicane C., et al. Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J. Lipid Res. 2014, 55:226-238.
83. Jiang H., Zhang J., Du Y., et al. microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator. Atherosclerosis 2015, 243:523-532.
84. Vickers K.C., Palmisano B.T., Shoucri B.M., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell. Biol. 2011, 13:423-433.
85. Wagner J., Riwanto M., Besler C., et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1392-1400.
86. Jasinska M., Owczarek J., Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. 2007, 59:483-499.
87. Brautbar A., Ballantyne C.M. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat. Rev. Cardiol. 2011, 8:253-265.
88. Soh J., Iqbal J., Queiroz J., et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat. Med. 2013, 19:892-900.
89. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357:2109-2122.
90. Degoma E.M., Rader D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 2011, 8:266-277.
91. Janssen H.L., Reesink H.W., Lawitz E.J., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
92. van Rooij E. The art of microRNA research. Circ. Res. 2011, 108:219-234.